Reference is made to the contemplated consolidation of shares in Lifecare ASA
(the "Company") in a ratio of 13:1, as resolved by the extraordinary general
meeting of the Company held on 17 September 2024. Reference is further made to
the 54,519,478 warrants (the "Warrants") issued by the Company pursuant to
resolutions made by the extraordinary general meeting of the Company held on
16 May 2024. The Warrants shall, pursuant to their terms, be consolidated in
the same ratio as the shares (i.e. 13:1).

In order to deliver shares and warrants to persons who own a number of shares
and/or warrants that does not compute with the 13:1 ratio for the
consolidations, the Company will re-purchase up to 30.000 shares in the
Company and up to 7.500 Warrants in the Company, for delivery to such persons.
The purchases will be carried out as ordinary trades in the market.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")
on the sensor body for read-out of pressure variations. Lifecare's sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

This information is subject to disclosure requirements pursuant to the
Norwegian Securities Trading Act section 5-12.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-09-25 07:00 CEST.